Compare AIV & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIV | CGEM |
|---|---|---|
| Founded | 1975 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 837.1M | 780.4M |
| IPO Year | 1996 | 2020 |
| Metric | AIV | CGEM |
|---|---|---|
| Price | $5.79 | $13.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $10.00 | ★ $28.80 |
| AVG Volume (30 Days) | ★ 1.7M | 694.4K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | ★ 62.59% | N/A |
| EPS Growth | ★ 35.34 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $208,679,000.00 | N/A |
| Revenue This Year | $6.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.27 | ★ N/A |
| Revenue Growth | ★ 11.60 | N/A |
| 52 Week Low | $5.24 | $5.68 |
| 52 Week High | $9.13 | $14.02 |
| Indicator | AIV | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 48.46 | 68.03 |
| Support Level | $5.79 | $11.40 |
| Resistance Level | $6.04 | $12.55 |
| Average True Range (ATR) | 0.09 | 0.94 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 27.45 | 96.11 |
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. Development and Redevelopment segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. Operating segment includes 20 residential apartment communities with 5,243 apartment homes that have achieved a stabilized level of operations. Other segment includes The Benson Hotel, company's only hotel. Majority of revenue is gained from Operating Segment.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.